Syngen Biotech Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
July 27, 2022 at 05:38 pm EDT
Share
Syngen Biotech Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 494.91 million compared to TWD 384.26 million a year ago. Net income was TWD 95.78 million compared to TWD 61.08 million a year ago. Basic earnings per share from continuing operations was TWD 3.53 compared to TWD 2.25 a year ago. Diluted earnings per share from continuing operations was TWD 3.53 compared to TWD 2.25 a year ago.
For the six months, sales was TWD 873.59 million compared to TWD 689.67 million a year ago. Net income was TWD 161.11 million compared to TWD 102.49 million a year ago. Basic earnings per share from continuing operations was TWD 5.94 compared to TWD 3.78 a year ago. Diluted earnings per share from continuing operations was TWD 5.94 compared to TWD 3.78 a year ago.
Syngen Biotech Co Ltd is a Taiwan-based company mainly engaged in the manufacture and distribution of active pharmaceutical ingredients and health food products. The Companyâs products mainly consist of active pharmaceutical ingredients, health food raw materials, medical equipment, such as bone density analyzers, blood glucose analyzers and biochemical analyzers, as well as animal health products and others. The Company distributes its products mainly in Taiwan, Iran, South Korea and Egypt.